By Robert Michel, from the Volume XVII No. 5 - March 29, 2010 issue
CEO SUMMARY: One aspect of the massive new health bill is that medical device companies will pay a 2.3% tax, effective January 1, 2013. Students of economics know that it is customers who invariably end up paying such direct taxes. Thus, clinical laboratories in the United States should prepare to see this 2.3% tax show
By Robert Michel, from the Volume XVII No. 2 - January 25, 2010 issue
CEO SUMMARY: In looking how to propel its business to the next level, the partners at Pathology, Inc., opted not to sell their pathology group practice. Instead, they chose to raise capital by selling equity in their company to a group of investors. In this exclusive interview, executives from Pathology, Inc., share their business strategy.
By Robert Michel, from the Volume XVII No. 1 - January 4, 2010 issue
CEO SUMMARY: In presenting this list of macro trends for clinical laboratories, several themes are in play. They range from a continued emphasis on improving lab operations to the need to acquire and deploy sophisticated information technology. During the next few years, the long-predicted retirement of Baby Boomers will kick in. That will aggravate the
By Robert Michel, from the Volume XVI No. 13 - September 21, 2009 issue
CEO SUMMARY: A bill that may be the U.S. Senate’s framework for reforming the U.S. healthcare system calls for a tax of $750 million per year to be paid by lab testing companies. The proposed bill also calls for a reduction in Medicare reimbursement for lab testing. One positive element was that reinstatement of the
By Robert Michel, from the Volume XVI No. 9 - June 29, 2009 issue
CEO SUMMARY: Annual healthcare spending now pushes past $2.5 trillion and this summer’s debate about how to best reform healthcare in the United States will be raucous and emotional. For the laboratory testing industry, the stakes are immense. THE DARK REPORT identifies two primary threats to the lab testing profession. One is spending cuts to
